Literature DB >> 3316243

Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker.

A Grauer1, F Raue, E Rix, C Tschahargane, R Ziegler.   

Abstract

Neuron-specific enolase (NSE) is an enzyme detectable in nervous and neuroendocrine tissue. Increased serum levels of NSE are found in small cell lung cancer and in patients with neuroblastoma, in whom NSE is used as a serum tumor marker. We have investigated 32 patients with histologically proven medullary thyroid carcinoma, a tumor of neuroendocrine origin, in which the classical tumor marker calcitonin (CT) was pathologically elevated. Positive immunocytochemistry for NSE and CT in C-cells was obtained in all cases. Increased serum NSE levels were found in only 5 of 32 patients, there was no correlation between NSE and CT concentrations. We also compared NSE and CT serum levels during long-term follow-up and again found no correlation between NSE and CT. After i.v. stimulation tests with pentagastrin and calcium, no correlation was found between NSE and CT serum levels. We conclude, therefore, that in medullary thyroid carcinoma NSE is useful for immunocytochemistry but not a reliable serum tumor marker.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316243     DOI: 10.1007/BF00390873

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells.

Authors:  D Schmechel; P J Marangos; M Brightman
Journal:  Nature       Date:  1978 Dec 21-28       Impact factor: 49.962

2.  Serum neuron-specific enolase in "non-functioning" islet-cell carcinoma.

Authors:  R A Prinz; P J Marangos
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

3.  [The determination of calcitonin for hospital use (author's transl)].

Authors:  F Raue; H Minne; D Schäfer; R Ziegler
Journal:  MMW Munch Med Wochenschr       Date:  1977-02-18

4.  Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations.

Authors:  J M Nesland; R Holm; J V Johannessen; V E Gould
Journal:  J Pathol       Date:  1986-01       Impact factor: 7.996

5.  Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer.

Authors:  D N Carney; P J Marangos; D C Ihde; P A Bunn; M H Cohen; J D Minna; A F Gazdar
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

6.  Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase.

Authors:  S Simpson; A I Vinik; P J Marangos; R V Lloyd
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

7.  The value of immunohistochemistry in medullary thyroid carcinoma: a systematic study of 30 cases.

Authors:  K Krisch; I Krisch; G Horvat; N Neuhold; W Ulrich
Journal:  Histopathology       Date:  1985-10       Impact factor: 5.087

8.  Different effects of hypercalcemic state induced by Walker tumor (HWCS 256) and 1,25 (OH)D3 intoxication on rat thyroid C cells. An ultrastructural, immunocytochemical, and biochemical study.

Authors:  E Rix; F Raue; I Deutschle; R Ziegler
Journal:  Histochemistry       Date:  1984

9.  Calcitonin as a tumor marker. Use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma.

Authors:  D Goltzman; J T Potts; R C Ridgway; F Maloof
Journal:  N Engl J Med       Date:  1974-05-09       Impact factor: 91.245

10.  Calcitonin, carcinoembryonic antigen and neuron-specific enolase in medullary thyroid carcinoma.

Authors:  R V Lloyd; J C Sisson; P J Marangos
Journal:  Cancer       Date:  1983-06-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.